• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 26, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Minority kidney transplants could increase with new option

Bioengineer by Bioengineer
January 31, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Study enhances options for kidney transplant patients with blood type B

Kidney transplant recipients are now benefiting from donor organs that do not match their blood type but are compatible and just as safe, according to a Vanderbilt University Medical Center study in the Journal of the American College of Surgeons.

The study’s finding is significant because roughly 15 percent of the population has blood type B, which is more common in African-Americans, and those patients have historically been transplanted at lower rates due to a lack of available organs.

The Vanderbilt study shows that blood type B patients can receive blood type A2 kidneys with similar outcomes.

Lead author David Shaffer, MD, professor of Surgery and Chief of Kidney and Pancreas Transplant, said more than 400 of the roughly 1,000 patients on the Vanderbilt waitlist for a kidney are African-Americans.

“This is a significant move at Vanderbilt and our region as over 40 percent of our patients are African-Americans,” Shaffer said. “It should improve access to transplants for our patient population.”

The United Network for Organ Sharing (UNOS) has allowed centers to use blood group A2 kidneys for B recipients since December 2014 without obtaining a waiver, seeking to make more organs available to B patients while reducing disparities in wait times. Vanderbilt’s study sought to determine the results of the policy change.

“Our study shows that the UNOS policy to increase access to kidney transplantation for minorities works,” Shaffer said. “This is a significant option for centers to adopt to reduce the disparity and increase access to kidney transplants for blood group B recipients who are principally ethnic minorities.”

The study analyzed outcomes at Vanderbilt from December 2014 through December 2017, including patient and graft survival, transplant wait time, serum creatinine and eGFR (estimated glomerular filtration rate), hospital costs, post-transplant anti-A titers, and their change relative to pre-transplant.

Even with the new availability, the study notes a recent UNOS analysis showed only 4.5 percent of waitlisted B recipients were registered as eligible for A2 donor kidneys, the result of issues with titers thresholds, patient eligibility and increased costs.

Transplant programs, regulators and payors will need to weigh improved access for minorities with the increased costs involved, study authors said.

Pre-transplant anti-A titer screening added total costs of $76,550 over the three-year study period, excluding additional coordinator time costs.

A2 to B had significantly higher mean transplant total hospital costs ($114,638 vs $91,697 for B to B transplantation) and mean hospital costs net organ acquisition costs ($42,356 vs $20,983).

###

Media Contact
Craig Boerner
[email protected]
615-322-4747
http://dx.doi.org/10.1016/j.jamcollsurg.2018.12.023

Tags: Medicine/HealthSurgeryTransplantation
Share12Tweet8Share2ShareShareShare2

Related Posts

Unraveling Ferroptosis in Esophageal Cancer Therapy

August 26, 2025

Impact of Iranian Medicinal Plants on Pancreatic Cancer

August 25, 2025

One-Year Outcomes for Severe Anorexia Nervosa Treatment

August 25, 2025

Assessing China’s Hospital Violence Prevention Policies

August 25, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    145 shares
    Share 58 Tweet 36
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unraveling Ferroptosis in Esophageal Cancer Therapy

Impact of Iranian Medicinal Plants on Pancreatic Cancer

One-Year Outcomes for Severe Anorexia Nervosa Treatment

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.